GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (STU:AWK) » Definitions » E10

Avadel Pharmaceuticals (STU:AWK) E10 : €-0.93 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Avadel Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Avadel Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was €-0.276. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.93 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was -18.70% per year. During the past 5 years, the average E10 Growth Rate was -11.60% per year. During the past 10 years, the average E10 Growth Rate was -1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Avadel Pharmaceuticals was 24.20% per year. The lowest was -21.60% per year. And the median was -6.00% per year.

As of today (2024-06-07), Avadel Pharmaceuticals's current stock price is €13.60. Avadel Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was €-0.93. Avadel Pharmaceuticals's Shiller PE Ratio of today is .


Avadel Pharmaceuticals E10 Historical Data

The historical data trend for Avadel Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals E10 Chart

Avadel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.60 -0.50 -0.69 -0.93 -1.03

Avadel Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.01 -0.89 -1.01 -1.03 -0.93

Competitive Comparison of Avadel Pharmaceuticals's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Avadel Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avadel Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avadel Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Avadel Pharmaceuticals's Shiller PE Ratio falls into.



Avadel Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Avadel Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.276/120.9901*120.9901
=-0.276

Current CPI (Mar. 2024) = 120.9901.

Avadel Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 -0.405 100.773 -0.486
201409 -0.202 100.474 -0.243
201412 -0.584 99.576 -0.710
201503 0.249 99.975 0.301
201506 -0.374 100.573 -0.450
201509 -0.615 100.274 -0.742
201512 1.607 99.676 1.951
201603 -0.135 99.676 -0.164
201606 -0.427 101.072 -0.511
201609 -0.428 100.274 -0.516
201612 0.104 99.676 0.126
201703 0.570 100.374 0.687
201706 0.605 100.673 0.727
201709 0.436 100.474 0.525
201712 -0.203 100.075 -0.245
201803 -0.260 100.573 -0.313
201806 -0.077 101.072 -0.092
201809 -0.369 101.371 -0.440
201812 -1.503 100.773 -1.805
201903 -0.310 101.670 -0.369
201906 -0.204 102.168 -0.242
201909 -0.218 102.268 -0.258
201912 -0.063 102.068 -0.075
202003 -0.018 102.367 -0.021
202006 0.435 101.769 0.517
202009 -0.170 101.072 -0.204
202012 -0.156 101.072 -0.187
202103 -0.193 102.367 -0.228
202106 -0.274 103.364 -0.321
202109 -0.323 104.859 -0.373
202112 -0.336 106.653 -0.381
202203 -0.409 109.245 -0.453
202206 -1.012 112.779 -1.086
202209 -0.333 113.504 -0.355
202212 -0.415 115.436 -0.435
202303 -0.448 117.609 -0.461
202306 -0.766 119.662 -0.775
202309 -0.384 120.749 -0.385
202312 -0.266 120.749 -0.267
202403 -0.276 120.990 -0.276

Add all the adjusted EPS together and divide 10 will get our e10.


Avadel Pharmaceuticals  (STU:AWK) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Avadel Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Avadel Pharmaceuticals (STU:AWK) Business Description

Traded in Other Exchanges
Address
10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.